AIBioTech Awarded $21 Million Government Contract  
8/16/2010 7:19:48 AM

RICHMOND, Va.--(BUSINESS WIRE)--American International Biotechnology Services (AIBioTech), a division of Bostwick Laboratories, Richmond, VA, today announced that it is one of four contractors awarded a new government contract valued at approximately $21 million. AIBioTech provides integrated research and development sciences and clinical testing services to physicians and life sciences investigators in biotechnology and pharmaceutical companies, academic institutions, and government agencies. The new contract will be funded in phases, with the first AIBioTech phase valued at nearly $3 million. AIBioTech has assembled a consortium of seven leading technology and biotechnology companies who are poised to meet all of the anticipated scientific objectives.

“This new contract marks a significant milestone for our company,” explained Dr Robert B. Harris, President and CSO, AIBioTech, and Program Director for the new contract effort. “The quality of our work for the government is well recognized, and the awarding of this contract shows that we can successfully compete with the foremost contractors in the country. We look forward to beginning work in September."

Bill Miller, CEO, AIBioTech adds, “As a company, we are seeking a balance in our revenue streams between clinical testing and development projects for private sector and government customers. Besides being the largest contract in our company’s history, this new project demonstrates the recognition of our competencies and puts AIBioTech in league with the very best bio-defense contractors in the country."

About AIBioTech

AIBioTech is a comprehensive Contract Research Organization which provides research services, drug development, assay development, and clinical testing services to organizations involved in life sciences research and in bringing new products to market. Core laboratory services include molecular biology, microbiology, virology, immunochemistry, peptide, bioorganic, protein and bioanalytical chemistries.

AIBioTech provides consultation on experimental design and offers services under GLP and non-GLP compliance. These services are offered individually or can be integrated to support product development from discovery to market with full Regulatory Support under FDA GLP Guidelines 21 CFR 58. Visit AIBioTech on the web at